Trial · NCT02057640
Adverse events110
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 110
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | anemia | Blood and lymphatic system disorders | DL1 - 3mg Lxazomib | 1 | 4 | |
| other | anemia | Blood and lymphatic system disorders | DL2 - 4mg Lxazomib | 4 | 12 | |
| other | Lymphocyte count decreased | Blood and lymphatic system disorders | DL1 - 3mg Lxazomib | 0 | 4 | |
| other | Lymphocyte count decreased | Blood and lymphatic system disorders | DL2 - 4mg Lxazomib | 4 | 12 | |
| other | Lymphocyte count increased | Blood and lymphatic system disorders | DL1 - 3mg Lxazomib | 0 | 4 | |
| other | Lymphocyte count increased | Blood and lymphatic system disorders | DL2 - 4mg Lxazomib | 1 | 12 | |
| other | Neutrophil count decreased | Blood and lymphatic system disorders | DL1 - 3mg Lxazomib | 0 | 4 | |
| other | Neutrophil count decreased | Blood and lymphatic system disorders | DL2 - 4mg Lxazomib | 3 | 12 | |
| other | Platelet count decreased | Blood and lymphatic system disorders | DL1 - 3mg Lxazomib | 1 | 4 | |
| other | Platelet count decreased | Blood and lymphatic system disorders | DL2 - 4mg Lxazomib | 4 | 12 | |
| other | White blood cell decreased | Blood and lymphatic system disorders | DL1 - 3mg Lxazomib | 0 | 4 | |
| other | White blood cell decreased | Blood and lymphatic system disorders | DL2 - 4mg Lxazomib | 3 | 12 | |
| other | creatinine increased | Investigations | DL1 - 3mg Lxazomib | 0 | 4 | |
| other | creatinine increased | Investigations | DL2 - 4mg Lxazomib | 2 | 12 | |
| other | dizziness | Nervous system disorders | DL1 - 3mg Lxazomib | 0 | 4 | |
| other | dizziness | Nervous system disorders | DL2 - 4mg Lxazomib | 2 | 12 | |
| other | anorexia | Metabolism and nutrition disorders | DL1 - 3mg Lxazomib | 0 | 4 | |
| other | anorexia | Metabolism and nutrition disorders | DL2 - 4mg Lxazomib | 2 | 12 | |
| other | fever | General disorders | DL1 - 3mg Lxazomib | 0 | 4 | |
| other | fever | General disorders | DL2 - 4mg Lxazomib | 2 | 12 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02057640/events